Lixivaptan (BioDeep_00000858617)
代谢物信息卡片
Lixivaptan
化学式: C27H21ClFN3O2 (473.1306248)
中文名称: 利赛伐坦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(C=C(C=C1)F)C(=O)NC2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl
InChI: InChI=1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33)
描述信息
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D04752
- PubChem: 172997
- DrugBank: DB06666
- ChEMBL: CHEMBL49429
- CAS: 168079-32-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Guy Decaux. Low Creatininuria due to Hyponatremia Is Reversible in Many Patients.
Nephron.
2022; 146(1):40-44. doi:
10.1159/000519049. [PMID: 34583361] - Annarita Di Mise, Xiaofang Wang, Hong Ye, Lorenzo Pellegrini, Vicente E Torres, Giovanna Valenti. Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
2021 10; 35(10):e21874. doi:
10.1096/fj.202100774r. [PMID: 34486176] - J L Woodhead, L Pellegrini, L K M Shoda, B A Howell. Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling.
Pharmaceutical research.
2020 Jan; 37(2):24. doi:
10.1007/s11095-019-2726-0. [PMID: 31909447] - Annarita Di Mise, Maria Venneri, Marianna Ranieri, Mariangela Centrone, Lorenzo Pellegrini, Grazia Tamma, Giovanna Valenti. Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells.
International journal of molecular sciences.
2019 Dec; 21(1):. doi:
10.3390/ijms21010183. [PMID: 31888044] - Xiaofang Wang, Megan M Constans, Fouad T Chebib, Vicente E Torres, Lorenzo Pellegrini. Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model.
American journal of nephrology.
2019; 49(6):487-493. doi:
10.1159/000500667. [PMID: 31117065] - Adnan A Kadi, Haitham Alrabiah, Mohamed W Attwa, Sabry Attia, Gamal A E Mostafa. Development and validation of HPLC-MS/MS method for the determination of lixivaptan in mouse plasma and its application in a pharmacokinetic study.
Biomedical chromatography : BMC.
2017 Nov; 31(11):. doi:
10.1002/bmc.4007. [PMID: 28493402] - Sunil Bhandari, Alessandro Peri, Iain Cranston, Rachael McCool, Alison Shaw, Julie Glanville, Larisa Petrakova, Karl O'Reilly. A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans.
Clinical endocrinology.
2017 Jun; 86(6):761-771. doi:
10.1111/cen.13315. [PMID: 28214374] - Fabrice Gankam Kengne, Bruno S Couturier, Alain Soupart, Guy Decaux. Urea minimizes brain complications following rapid correction of chronic hyponatremia compared with vasopressin antagonist or hypertonic saline.
Kidney international.
2015 Feb; 87(2):323-31. doi:
10.1038/ki.2014.273. [PMID: 25100046] - George Liamis, Theodosios D Filippatos, Moses S Elisaf. Treatment of hyponatremia: the role of lixivaptan.
Expert review of clinical pharmacology.
2014 Jul; 7(4):431-41. doi:
10.1586/17512433.2014.911085. [PMID: 24766294] - Yasukatsu Izumi, Katsuyuki Miura, Hiroshi Iwao. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Journal of pharmacological sciences.
2014; 124(1):1-6. doi:
10.1254/jphs.13r13cp. [PMID: 24401675] - Ruediger W Lehrich, David I Ortiz-Melo, Mehul B Patel, Arthur Greenberg. Role of vaptans in the management of hyponatremia.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2013 Aug; 62(2):364-76. doi:
10.1053/j.ajkd.2013.01.034. [PMID: 23725974] - Mitchell H Rosner. Lixivaptan: a vasopressin receptor antagonist for the treatment of hyponatremia.
Kidney international.
2012 Dec; 82(11):1154-6. doi:
10.1038/ki.2012.317. [PMID: 23151986] - William T Abraham, Johannes Hensen, Peter A Gross, Daniel G Bichet, Richard C Josiassen, DeoDatta S Chafekar, Cesare Orlandi. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia.
Kidney international.
2012 Dec; 82(11):1223-30. doi:
10.1038/ki.2012.275. [PMID: 22932119] - William T Abraham, Guy Decaux, Richard C Josiassen, Yoram Yagil, Nelson Kopyt, Hemant P Thacker, Massimo Mannelli, Daniel G Bichet, Cesare Orlandi. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia.
Kidney international.
2012 Dec; 82(11):1215-22. doi:
10.1038/ki.2012.274. [PMID: 22932122] - E Dahl, L L Gluud, N Kimer, A Krag. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
Alimentary pharmacology & therapeutics.
2012 Oct; 36(7):619-26. doi:
10.1111/apt.12025. [PMID: 22908905] - Chandra Prakash, Zhaoyang Li, Cesare Orlandi, Lewis Klunk. Assessment of exposure of metabolites in preclinical species and humans at steady state from the single-dose radiolabeled absorption, distribution, metabolism, and excretion studies: a case study.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Jul; 40(7):1308-20. doi:
10.1124/dmd.112.044933. [PMID: 22474055] - Gregory Valania, Manmeet Singh, Mara T Slawsky. Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?.
Current heart failure reports.
2011 Sep; 8(3):198-205. doi:
10.1007/s11897-010-0035-3. [PMID: 21046492] - Hammam D Zmily, Nazia S Khan, Suleiman Daifallah, Jalal K Ghali. The potential role for lixivaptan in heart failure and in hyponatremia.
Expert opinion on investigational drugs.
2011 Jun; 20(6):831-48. doi:
10.1517/13543784.2011.579102. [PMID: 21548825] - Jalal K Ghali, Hammam D Zmily, Jareer O Farah, Suleiman Daifallah. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
IDrugs : the investigational drugs journal.
2010 Nov; 13(11):782-92. doi:
NULL. [PMID: 21046526] - William T Abraham, Juan M Aranda, John P Boehmer, Uri Elkayam, Edward M Gilbert, Stephen S Gottlieb, Gerd Hasenfuss, Marrick Kukin, Brian D Lowes, John B O'Connell, Luigi Tavazzi, Arthur M Feldman, Barry Ticho, Cesare Orlandi. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study.
Clinical and translational science.
2010 Oct; 3(5):249-53. doi:
10.1111/j.1752-8062.2010.00217.x. [PMID: 20973922] - Benaya Rozen-Zvi, Dafna Yahav, Mihai Gheorghiade, Asher Korzets, Leonard Leibovici, Uzi Gafter. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2010 Aug; 56(2):325-37. doi:
10.1053/j.ajkd.2010.01.013. [PMID: 20538391] - Gina González Robledo, Diana Silva Cantillo, Josep Comín Colet. [Hyponatremia in heart failure: physiopathology and pharmacological approach].
Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.
2010 May; 57 Suppl 2(?):10-4. doi:
10.1016/s1575-0922(10)70017-6. [PMID: 21130957] - Carles Villabona. [Vasopressin receptor antagonists: the vaptans].
Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.
2010 May; 57 Suppl 2(?):41-52. doi:
10.1016/s1575-0922(10)70021-8. [PMID: 21130961] - Timothy Reilly, Michelle R Schork. Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.
The Annals of pharmacotherapy.
2010 Apr; 44(4):680-7. doi:
10.1345/aph.1m660. [PMID: 20332337] - Markus Haass. [Vasopressin receptor antagonists and heart failure].
Therapeutische Umschau. Revue therapeutique.
2009 Nov; 66(11):735-40. doi:
10.1024/0040-5930.66.11.735. [PMID: 19885790] - Siva K Kumar, Paul J Mather. AVP receptor antagonists in patients with CHF.
Heart failure reviews.
2009 Jun; 14(2):83-6. doi:
10.1007/s10741-008-9107-9. [PMID: 18766439] - Elaine Ku, Niloofar Nobakht, Vito M Campese. Lixivaptan: a novel vasopressin receptor antagonist.
Expert opinion on investigational drugs.
2009 May; 18(5):657-62. doi:
10.1517/13543780902889760. [PMID: 19379124] - Ferenc Laczi. [Etiology, diagnostics and therapy of hyponatremias].
Orvosi hetilap.
2008 Jul; 149(29):1347-54. doi:
10.1556/oh.2008.28409. [PMID: 18617466] - Dimitrios Farmakis, Gerasimos Filippatos, Dimitrios T Kremastinos, Mihai Gheorghiade. Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
Current heart failure reports.
2008 Jun; 5(2):91-6. doi:
10.1007/s11897-008-0015-z. [PMID: 18765079] - Teresa A Schweiger, Martin M Zdanowicz. Vasopressin-receptor antagonists in heart failure.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2008 May; 65(9):807-17. doi:
10.2146/ajhp070132. [PMID: 18436727] - Siva Kumar, Sharon Rubin, Paul J Mather, David J Whellan. Hyponatremia and vasopressin antagonism in congestive heart failure.
Clinical cardiology.
2007 Nov; 30(11):546-51. doi:
10.1002/clc.18. [PMID: 17847041] - Gourang P Patel, Robert A Balk. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
Clinical therapeutics.
2007 Feb; 29(2):211-29. doi:
10.1016/j.clinthera.2007.02.004. [PMID: 17472815] - Farhan Ali, Maya Guglin, Peter Vaitkevicius, Jalal K Ghali. Therapeutic potential of vasopressin receptor antagonists.
Drugs.
2007; 67(6):847-58. doi:
10.2165/00003495-200767060-00002. [PMID: 17428103] - A Greenberg, J G Verbalis. Vasopressin receptor antagonists.
Kidney international.
2006 Jun; 69(12):2124-30. doi:
10.1038/sj.ki.5000432. [PMID: 16672911] - Phuong-Chi T Pham, Phuong-Mai T Pham, Phuong-Thu T Pham. Vasopressin excess and hyponatremia.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2006 May; 47(5):727-37. doi:
10.1053/j.ajkd.2006.01.020. [PMID: 16632011] - Fuk Wah Sum, John Dusza, Efren Delos Santos, George Grosu, Marvin Reich, Xumei Du, J Donald Albright, Peter Chan, Joseph Coupet, Xun Ru, Hossein Mazandarani, Trina Saunders. Structure-activity study of novel tricyclic benzazepine arginine vasopressin antagonists.
Bioorganic & medicinal chemistry letters.
2003 Jul; 13(13):2195-8. doi:
10.1016/s0960-894x(03)00388-3. [PMID: 12798333] - James Walter Ferguson, George Therapondos, David E Newby, Peter Clive Hayes. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Clinical science (London, England : 1979).
2003 Jul; 105(1):1-8. doi:
10.1042/cs20030062. [PMID: 12639215] - Alexander L Gerbes, Veit Gülberg, Pere Ginès, Guy Decaux, Peter Gross, Hassan Gandjini, Jacques Djian. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.
Gastroenterology.
2003 Apr; 124(4):933-9. doi:
10.1053/gast.2003.50143. [PMID: 12671890] - Florence Wong, Andres T Blei, Laurence M Blendis, Paul J Thuluvath. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Hepatology (Baltimore, Md.).
2003 Jan; 37(1):182-91. doi:
10.1053/jhep.2003.50021. [PMID: 12500203] - Alexey B Dyatkin, William J Hoekstra, Dennis J Hlasta, Patricia Andrade-Gordon, Lawrence de Garavilla, Keith T Demarest, Joseph W Gunnet, William Hageman, Richard Look, Bruce E Maryanoff. Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity.
Bioorganic & medicinal chemistry letters.
2002 Nov; 12(21):3081-4. doi:
10.1016/s0960-894x(02)00649-2. [PMID: 12372506] - Dominique Guyader, Alain Patat, Evelyn J Ellis-Grosse, Gayle P Orczyk. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.
Hepatology (Baltimore, Md.).
2002 Nov; 36(5):1197-205. doi:
10.1053/jhep.2002.36375. [PMID: 12395330] - G Decaux. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
The Journal of laboratory and clinical medicine.
2001 Jul; 138(1):18-21. doi:
10.1067/mlc.2001.116025. [PMID: 11433224] - C Serradeil-Le Gal, D Raufaste, E Double-Cazanave, G Guillon, C Garcia, M Pascal, J P Maffrand. Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
Kidney international.
2000 Oct; 58(4):1613-22. doi:
10.1046/j.1523-1755.2000.00322.x. [PMID: 11012895] - P Y Martin, W T Abraham, X Lieming, B R Olson, R M Oren, M Ohara, R W Schrier. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure.
Journal of the American Society of Nephrology : JASN.
1999 Oct; 10(10):2165-70. doi:
10.1681/asn.v10102165. [PMID: 10505693] - V Aranapakam, J D Albright, G T Grosu, E G Delos Santos, P S Chan, J Coupet, X Ru, T Saunders, H Mazandarani. 5-fluoro-2-methyl-N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepine-10(11H)-yl carbonyl)-2-pyridinyl]benzamide (CL-385004) and analogs as orally active arginine vasopressin receptor antagonists.
Bioorganic & medicinal chemistry letters.
1999 Jul; 9(13):1737-40. doi:
10.1016/s0960-894x(99)00279-6. [PMID: 10406633] - J D Albright, M F Reich, E G Delos Santos, J P Dusza, F W Sum, A M Venkatesan, J Coupet, P S Chan, X Ru, H Mazandarani, T Bailey. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
Journal of medicinal chemistry.
1998 Jul; 41(14):2442-4. doi:
10.1021/jm980179c. [PMID: 9651149] - P S Chan, J Coupet, H C Park, F Lai, D Hartupee, P Cervoni, J P Dusza, J D Albright, X Ru, H Mazandarani, T Tanikella, C Shepherd, L Ochalski, T Bailey, T Y Lock, X Ning, J R Taylor, W Spinelli. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist.
Advances in experimental medicine and biology.
1998; 449(?):439-43. doi:
10.1007/978-1-4615-4871-3_55. [PMID: 10026835]